LDL-Cholesterol-Lowering Therapy-Reference-Cited by-同舟云学术

LDL-Cholesterol-Lowering Therapy

Published:2020 Issue: Volume: Page:
ISSN:0171-2004
Container-title:Handbook of Experimental Pharmacology
language:
Short-container-title:

Author:

Pirillo Angela,Norata Giuseppe D.,Catapano Alberico L.

Abstract

AbstractThe causal relation between elevated levels of LDL-C and cardiovascular disease has been largely established by experimental and clinical studies. Thus, the reduction of LDL-C levels is a major target for the prevention of cardiovascular disease. In the last decades, statins have been used as the main therapeutic approach to lower plasma cholesterol levels; however, the presence of residual lipid-related cardiovascular risk despite maximal statin therapy raised the need to develop additional lipid-lowering drugs to be used in combination with or in alternative to statins in patients intolerant to the treatment. Several new drugs have been approved which have mechanisms of action different from statins or impact on different lipoprotein classes.

Publisher

Springer Berlin Heidelberg

Link

https://link.springer.com/content/pdf/10.1007/164_2020_361

Reference157 articles.

1. Ahn CH, Choi SH (2015) New drugs for treating dyslipidemia: beyond statins. Diabetes Metab J 39:87–94. https://doi.org/10.4093/dmj.2015.39.2.87

2. Akdim F, Stroes ES, Sijbrands EJ et al (2010a) Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 55:1611–1618. https://doi.org/10.1016/j.jacc.2009.11.069

3. Akdim F, Visser ME, Tribble DL et al (2010b) Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 105:1413–1419. https://doi.org/10.1016/j.amjcard.2010.01.003

4. Akdim F, Tribble DL, Flaim JD et al (2011) Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J 32:2650–2659. https://doi.org/10.1093/eurheartj/ehr148

5. Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278. https://doi.org/10.1016/S0140-6736(05)67394-1

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The German CaRe high registry for familial hypercholesterolemia – Sex differences, treatment strategies, and target value attainment;Atherosclerosis Plus;2023-09

2. The burden of hypercholesterolemia and ischemic heart disease in an ageing world;Pharmacological Research;2023-07

3. Serum Low Density Lipoprotein Cholesterol Concentration Is Not Dependent on Cholesterol Synthesis and Absorption in Healthy Humans;Nutrients;2022-12-17

4. Intervention time decides the status of autophagy, NLRP3 activity and apoptosis in macrophages induced by ox‐LDL;Lipids in Health and Disease;2022-10-25

5. Crosstalk between dendritic cells and T lymphocytes during atherogenesis: Focus on antigen presentation and break of tolerance;Frontiers in Cardiovascular Medicine;2022-07-28